Press Releases

October 26, 2020

Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients

Clinical Evidence Supports Efficacy of Theranica’s Prescribed Digital Therapeutic in Adult Chronic Migraine Patients
Read More
September 17, 2020

Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica’s Nerivio® Device

Peer-Reviewed Post-Marketing Surveillance Study Tested Efficacy and Safety of Remote Electrical Neuromodulation (REN) in Acute Treatment of Migraine
Read More
September 8, 2020

Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021
Read More
July 16, 2020

KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica

Nerivio®, a novel wireless neuromodulation wearable from Theranica for drug-free acute treatment of migraine, features an electronic housing molded in a THERMOLAST® M custom-colored medical-grade thermoplastic elastomer compound from KRAIBURG TPE. 
Read More
July 15, 2020

Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

New Peer-Reviewed Article Publishes Results of Clinical Study Testing Efficacy of Remote Electrical Neuromodulation in Acute Treatment of Migraine in Chronic Migraine Patients
Read More
June 1, 2020

Theranica Kicks Off Migraine Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable

Amid COVID-19, Patients Report Greater Incidence of Stress-Related Migraines
Read More
May 18, 2020

Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device

During Initial Limited Commercial Launch, Nerivio® Was Used more than 30,000 Times to Address Migraine Pain and other Symptoms
Read More
April 6, 2020

Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform

FDA-Authorized Drug-Free Migraine Treatment Device Available by Prescription through One-Stop Telemedicine Platform
Read More
March 10, 2020

Theranica Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020

Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine, Recognized as a Leading Biotech Innovator
Read More
February 25, 2020

Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove

Cove Provides Rapid Consultation with a Licensed Physician and Home Delivery of the Novel FDA-Authorized Prescribed Wearable Device
Read More
December 18, 2019

Theranica Named 2020 ‘Game Changer’ by CB Insights

BioMed Tech Developer Included in “Electro-Charged Therapeutics” Category Recognizing Companies Creating a Drug-Free Future
Read More
December 3, 2019

Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio

Review Highlights Efficacy and Safety of Smartphone-Controlled Prescribed Wearable for the Acute Treatment of Migraine
Read More
November 21, 2019

Theranica’s Nerivio™ Named in TIME’s List of 100 Best Inventions of 2019

Acute Migraine Smartphone-Controlled Prescription Wearable Recognized in Health Care Category
Read More
November 18, 2019

Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production

Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable
Read More
July 23, 2019

New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

Headache Researchers in California and Missouri Conducted a Per-Patient Comparison of FDA-Cleared Wearable Device with Contemporary Usual Care
Read More
June 24, 2019

Theranica Appoints Senior Executives to Lead its New USA Subsidiary

New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio™ for Acute Treatment of Migraine
Read More
May 28, 2019

FDA Grants Theranica De Novo to Market First Smartphone-Controlled Acute Migraine-Relief Wearable Device

Clinical Data Show 66.7% Pain Relief Response Within Two Hours
Read More
May 13, 2019

OMRON VENTURES Joins Theranica’s Series B Funding Round as Strategic Investor

Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management
Read More
March 18, 2019

Theranica Raises $35M to Bring Innovative Migraine Device to the USA aMoon leads round B of financing of the Israel-based company

aMoon leads round B of financing of the Israel-based company
Read More
November 15, 2018

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

Results of largest study with a migraine device solidify safety, efficacy and tolerability of the drug-free Nerivio Migra, offering huge clinical benefit for migraineurs
Read More
July 03, 2017

Theranica Raises $6M to Combat Migraine

Lightspeed leads round A of financing in Israel-based advanced e-health company
Read More